Feldstudie zur simultanen Vakzination gegen das porzine Circovirus Typ 2 und Mycoplasma hyopneumoniae

E. Herbich; B. Heissenberger; A. Ladinig; A. Griessler; M. Ritzmann; C. Weissenbacher-Lang; I. Hennig-Pauka

doi:10.1055/s-0038-1623189

Tierärztliche Praxis Ausgabe G: Großtiere / Nutztiere, Table of Contents

Tierarztl Prax Ausg G Grosstiere Nutztiere 2013; 41(05): 279-288
DOI: 10.1055/s-0038-1623189

Originalartikel

Schattauer GmbH

Feldstudie zur simultanen Vakzination gegen das porzine Circovirus Typ 2 und Mycoplasma hyopneumoniae

Field trial on the simultaneous vaccination against porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae

E. Herbich

¹Klinik für Schweine der Veterinärmedizinischen Universität Wien

,

B. Heissenberger

¹Klinik für Schweine der Veterinärmedizinischen Universität Wien

,

A. Ladinig

¹Klinik für Schweine der Veterinärmedizinischen Universität Wien

,

A. Griessler

²TraunkreisVetClinic, Ried im Traunkreis, Österreich

,

M. Ritzmann

¹Klinik für Schweine der Veterinärmedizinischen Universität Wien

³Klinik für Schweine, Ludwig-Maximilians-Universität München

,

C. Weissenbacher-Lang

⁴Institut für Pathologie und Gerichtliche Veterinärmedizin der Veterinärmedizinischen Universität Wien

,

I. Hennig-Pauka

¹Klinik für Schweine der Veterinärmedizinischen Universität Wien

› Author Affiliations

Abstract

Zusammenfassung

Ziel war zu prüfen, ob die an einer oder zwei Injektionsstellen durchgeführte simultane Applikation zweier Vakzinen gegen das porzine Circovirus Typ 2 (PCV2) bzw. Mycoplasma hyopneumoniae (M. hyo.) bei Saugferkeln ebenso wirksam ist wie die Verabreichung der einzelnen Impfstoffe. Material und Methoden: 598 Ferkel bildeten bei gemischter Aufstallung fünf Versuchsgruppen. Das Plazebo Porcilis^® Diluvac forte sowie die Vakzinen Porcilis^® M HYO („M HYO“) und Porcilis^® PCV („PCV“) wurden jeweils in der 1. und 3. Lebenswoche (LW) wie folgt appliziert: Gruppe A: Plazebo/PCV, Gruppe B: M HYO/M HYO, Gruppe C: Plazebo/Plazebo, Gruppe D: M HYO/M HYO + PCV (kombinierte Einzeldosis), Gruppe E: Plazebo/M HYO + PCV (getrennte Injektionsstellen). Die Wirkung der simultanen Impfung wurde anhand von Tageszunahmen, pathomorphologischer Lungenveränderungen, Morbidität, Mortaliät und der Immunantwort gegen die verwendeten Antigene bestimmt. Die Verträglichkeit der simultanen Vakzination wurde anhand lokaler und systemischer Impfreaktionen bewertet. Ergebnisse: Die phasenweise schlechte Bestandsgesundheit, bedingt durch Saugferkeldurchfälle (n = 111) in der 1.–3. LW, ließ sich nicht eindeutig mit PCV2 in Zusammenhang bringen. Dennoch zeigten alle geimpften Tiere tendenziell höhere Tageszunahmen als die Kontrolltiere. Unterschiede zwischen den Gruppen hinsichtlich Lungenveränderungen, Morbidität und Mortalität waren nicht signifikant. M.-hyo.- und PCV2-spezifische Antikörpertiter lagen bei geimpften Tieren signifikant höher als bei nicht geimpften. Bei je einem Ferkel der Gruppen A (PCV2) und C (Plazebo) kam es zu lokalen Impfreaktionen. Schlussfolgerung und klinische Relevanz: In Betrieben mit suboptimaler Bestandsgesundheit lässt sich ein positiver Effekt beider Impfungen nachweisen. Die simultane Impfung gegen PCV2 und M. hyo. hatte keine negativen Auswirkungen. In Bezug auf die Steigerung der durchschnittlichen Tageszunahmen war der Effekt der simultanen Impfungen dem der Einzelimpfungen gleichwertig. Der Einsatz der Simultanimpfung gegen M. hyo. und PCV2, der Vorteile hinsichtlich Arbeitsaufwand und Tierschutz bringt, kann daher in der Praxis befürwortet werden.

Summary

Objective: The objective of the present study was to investigate whether a combined or concurrent application of two vaccines against Mycoplasma hyopneumoniae (M. hyo.) and porcine circovirus type 2 (PCV2) in suckling piglets can be as effective as the single use of both products. Material and methods: A total of 598 piglets were allocated to five groups. In the 1st and 3rd weeks of life the placebo Porcilis^® Diluvac forte and the two vaccines Porcilis^® M HYO (“M HYO”) and Porcilis^® PCV (“PCV”) were administered according to the following scheme: group A: placebo/PCV; group B: M HYO/M HYO; group C: placebo/placebo; group D: M HYO/M HYO + PCV (combined single dose); group E: placebo/M HYO + PCV (different injection sites). Lung lesions due to M. hyo. infection were recorded at slaughter, and average daily weight gain, morbidity, mortality, serum PCV2 load and specific humoral immune responses were compared between the groups. Local and systemic side effects were recorded. Results: Sporadic impairment of the herd health status due to piglet diarrhoea (n = 111) from the 1st to 3rd weeks of life were not associated with M. hyo. or PCV2. A tendency towards a higher average daily weight gain was found in vaccinated pigs compared to the control group. Slight differences between groups in terms of lung lesions, morbidity and mortality were not significant. M. hyo. and PCV2 antibody-titers were significantly higher in vaccinated than in non-vaccinated pigs. One pig from both group A (PCV2) and group C (placebo) displayed local reactions at the vaccination site. Conclusion and clinical relevance: A positive effect on animal health can be achieved by vaccination against M. hyo. and PCV2 in herds with suboptimal health status. A simultaneous vaccination either by a combined or concurrent application has no negative effect on health status. Simultaneous vaccination yielded the same positive effect on average daily weight gain as single vaccinations. Therefore, a simultaneous vaccination against M. hyo. and PCV2, which reduces workload and is beneficial for animal welfare, can be recommended.

Schlüsselwörter

Atemwegserkrankung - Porcine respiratory disease complex (PRDC) - Postweaning Multisystemic Wasting Syndrome (PMWS) - PCV2 - Kombinationsvakzine - Schwein

Key words

Respiratory disease - porcine respiratory disease complex (PRDC) - post-weaning multisystemic wasting syndrome (PMWS) - field trial - combined vaccine

Full Text

References

Literatur
1 Alarcon P, Velasova M, Werling D, Stärk K, Chang Y, Nevel A, Pfeiffer D, Wieland B. Assessment and quantification of post-weaning multi-systemic wasting syndrome severity at farm level. Prev Vet Med 2011; 98 (01) 19-28.
2 Allan GM. Porcine circovirus: a review. Vet Diagn Invest 2000; 12: 3-14.
3 Bukovsky C, Schmoll F, Revilla-Fernandez S, Weissenböck H. Studies on the aetiology of non-suppurative encephalitis in pigs. Vet Rec 2007; 161: 552-558.
4 Fort M, Sibila M, Allepuz A, Mateu E, Roerink F, Segales J. Porcine circovirus type 2 (PCV2) vaccination of conventional pigs prevents viremia against PCV2 isolates of different genotypes and geographic origins. Vaccine 2008; 26: 1063-1071.
5 Fort M, Sibila M, Perez-Martin E, Nofrarias M, Mateu M, Segales J. One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model. Vaccine 2009; 27: 4031-4037.
6 Fraile L, Sibila M, Nofrarías M, López-Jimenez R, Huerta E, Llorens A, López-Soria S, Pérez D, Segalés J. Effect of sow and piglet porcine circovirus type 2 (PCV2) vaccination on piglet mortality, viraemia, antibody titre and production parameters. Vet Microbiol 2012; 161 (1–2) 229-234.
7 Gillespie J, Opriessnig T, Meng XJ, Pelzer K, Buechner-Maxwell V. Porcine circovirus type 2 and porcine circovirus-associated disease. J Vet Intern Med 2009; 23: 1151-1163.
8 Goodwin RFW, Hodgson RG, Whittlestone P, Woodhams RL. Some experiments relating to artificial immunity in enzootic pneumonia of pigs. J Hyg Camb 1969; 67: 465.
9 Harding J, Clark EG. Recognizing and diagnosing post weaning multisystemic wasting syndrome. J Swine Health Prod 1997; 5: 201-203.
10 Horlen KP, Dritz SS, Nietfeld JC, Henry SC, Hesse RA, Oberst R, Hays M, Anderson J, Rowland RR. A field evaluation of mortality rate and growth performance in pigs vaccinated against porcine circo virus type 2. J Am Vet Med Assoc 2008; 232: 906-912.
11 Jensen CS, Ersboll AK, Nielsen IP. A meta-analysis comparing the effect of vaccines against Mycoplasma hyopneumoniae on daily weight gain in pigs. Prev Vet Med 2002; 54 (03) 265-278.
12 Kim J, Chung HK, Chae C. Association of porcine circovirus 2 with porcine respiratory disease complex. Vet J 2003; 166: 251-256.
13 Kim D, Kim CH, Han K, Seo HW, Oh Y, Park C, Kang I, Chae C. Comparative efficacy of commercial Mycoplasma hyopneumoniae and porcine circovirus 2 (PCV2) vaccines in pigs experimentally infected with M. hyopneumoniae and PCV2. Vaccine 2011; 29: 3206-3212.
14 Kixmöller M, Ritzmann M, Eddicks M, Saalmüller A, Elbers K, Fachinger V. Reduction of PMWS-associated clinical signs and CO1623189-infections by vaccination against PCV2. Vaccine 2008; 26: 3443-3451.
15 Lang C, Söllner H, Barz A, Ladinig A, Langhoff R, Weissenböck H, Kekarainen T, Segales J, Ritzmann M. Untersuchung zur Verbreitung des Torque-Virus beim Schwein in Österreich. Berl Münch Tierärztl Wschr 2011; 124: 142-147.
16 Lyoo K, Joo H, Caldwell B, Kim H, Davies P, Torrison J. Comparative efficacy of three commercial PCV2 vaccines in conventionally reared pigs. Vet J 2010; 189 (01) 58-62.
17 Madec F, Rose N, Grasland B, Cariolet R, Jestin A. Post-weaning multisystemic wasting syndrome and other PCV2-related problems in pigs: a 12-year experience. Transbound Emerg Dis 2008; 55 (07) 273-283.
18 Maes D, Segales J, Meyns T, Sibila M, Pieters M, Haesebrouck F. Control of Mycoplasma hyopneumoniae infections in pigs. Vet Microbiol 2008; 126: 297-309.
19 Maes D, Deluyker H, Verdonck Castryck F, Miry C, Vrijens B, Verbeke W, Viaene J, Kruif A. Effect of vaccination against Mycoplasma hyopneumoniae in pig herds with an all-in/all-out production system. Vaccine 1999; 17 (9–10) 1024-1034.
20 Martelli P, Ferrari L, Morganti M, Angelis E, Bonilauri P, Guazetti S, Caleffi A, Borghetti P. One dose of a porcine circovirus 2 subunit vaccine induces humoral and cell-mediated immunity and protects against porcine circovirus-associated disease under field conditions. Vet Microbiol 2011; 149 (3–4) 339-351.
21 Martelli P, Terreni M, Guazzetti S, Cavirani S. Antibody response to Mycoplasma hyopneumoniae infection in vaccinated pigs with or without maternal antibodies induced by sow vaccination. J Vet Med B Infect Dis Vet Public Health 2006; 53 (05) 229-233.
22 Nathues H, Beilage EG, Kreienbrock L, Rosengarten R, Spergser J. RAPD and VNTR analyses demonstrate genotypic heterogeneity of Mycoplasma hyopneumoniae isolates from pigs housed in a region with high pig density. Vet Microbiol 2011; 152 (3–4) 338-345.
23 Opriessnig T, Meng X, Halbur PG. Porcine circovirus type 2-associated disease: Update on current terminology, clinical manifestations, pathogenesis, diagnosis, and intervention strategies. J Vet Diagn lnvest 2007; 19: 591-615.
24 Opriessnig T, Patterson AR, Madson DM, Pal N, Halbur PG. Comparison of efficacy of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV-PCV2-SIV clinical infection model 2–3-months post vaccination. Vaccine 2009; 27 (07) 1002-1007.
25 Palzer A, Ritzmann M, Wolf G, Heinritzi K. Associations between pathogens in healthy pigs and pigs with pneumonia. Vet Rec 2008; 162 (09) 267-271.
26 Podgórska K, Stadejek T. Porcine circovirus type 2 viremia and seroconversion in pigs from a farm affected by postweaning multisystemic wasting syndrome. Pol J Vet Sci 2011; 14 (04) 667-669.
27 Redondo E, Masot AJ, Fernández A, Gázquez A. Histopathological and immunhistochemical findings in the lungs of pigs infected experimentally with Mycoplasma hyopneumoniae . J Comp Pathol 2009; 140 (04) 260-270.
28 Sibila M, Nofrarías M, López-Soria S, Segalés J, Valero O, Espinal A, Calsamiglia M. Chronological study of Mycoplasma hyopneumoniae infection, seroconversion and associated lung lesions in vaccinated and non-vaccinated pigs. Vet Microbiol 2007; 122 (1–2) 97-107.
29 Sorden. Update on porcine circovirus and postweaning multisystemic wasting syndrome. J Swine Health Prod 2000; 8 (03) 133-136.
30 Strait EL, Rapp-Gabrielson VJ, Erickson BZ, Evans RB, Taylor LP, Yonkers TK, Keich RL, Jolie R, Thacker EL. Efficacy of a Mycoplasma hyopneumoniae bacterin in pigs challenged with two contemporary pathogenic isolates of M. hyopneumoniae. . J Swine Health Prod 2008; 16 (04) 200-206.
31 Tzivara A, Kritas SK, Bourriel AR, Alexopoulos C, Kyriakis SC. Efficacy of an inactivated aqueous vaccine for the control of enzootic pneumonia in pigs infected with Mycoplasma hyopneumoniae . Vet Rec 2007; 160 (07) 225-229.
32 Guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs). European medicines agency. EMA/CVMP/IWP/594618/2010-CONSULTATION.
33 Guideline on the requirements for combined veterinary vaccines. European medicines agency. EMA/CVMP/IWP/52/97-FINAL.
34 Guideline on the requirements for concurrent administration of immunological veterinary medicinal products. European medicines agency. EMA/CVMP/550/02-FINAL.